Ideaya Biosciences Inc
$ 36.24
0.55%
06 Aug - close price
- Market Cap 3,488,999,000 USD
- Current Price $ 36.24
- High / Low $ 36.91 / 36.00
- Stock P/E N/A
- Book Value 10.67
- EPS -1.93
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -0.16 %
- 52 Week High 40.58
- 52 Week Low 22.38
About
IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California.
Analyst Target Price
$53.46
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-05 | 2026-02-17 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-13 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-07 |
| Reported EPS | -1.22 | -1.11 | -0.94 | 1.33 | -0.88 | -0.82 | -1.49 | -0.6 | -0.68 | -0.53 | -0.52 | -0.46 |
| Estimated EPS | -1.18 | -0.98 | -0.95 | -0.55 | -0.79 | -0.69 | -0.6225 | -0.63 | -0.53 | -0.5 | -0.46 | -0.5 |
| Surprise | -0.04 | -0.13 | 0.01 | 1.88 | -0.09 | -0.13 | -0.8675 | 0.03 | -0.15 | -0.03 | -0.06 | 0.04 |
| Surprise Percentage | -3.3898% | -13.2653% | 1.0526% | 341.8182% | -11.3924% | -18.8406% | -139.3574% | 4.7619% | -28.3019% | -6% | -13.0435% | 8% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IDYA
2026-08-05 20:12:00
IDEAYA Biosciences recently reported a wider Q2 2026 net loss of US$112.45 million, or US$1.22 per share, and an overall wider six-month loss compared to the previous year. Despite this, the company is advancing its precision oncology pipeline, initiating a monotherapy expansion for IDE892 and partnering with Roche for combination regimens in MTAP-deleted pancreatic cancer. The article suggests that while the company's valuation is high and it faces significant cash burn, these clinical advancements and partnerships could reshape its investment narrative, emphasizing the importance of trial progress over current earnings.
2026-08-05 16:12:17
IDEAYA Biosciences reported its second-quarter 2026 results, showing collaboration revenue of $8.86 million and a net loss of $(112.45) million, or $(1.22) diluted EPS, due to increased R&D and commercial preparation. The company highlighted positive Phase 2/3 clinical trial results for darovasertib, with an NDA submission planned for H2 2026, and ongoing advancements in its pipeline. Financial highlights include a significant increase in revenue from the prior year and a worsening net loss.
2026-08-05 12:40:52
Leerink Partners has decreased its target price for IDEAYA Biosciences, Inc. (IDYA.O) from $37 to $31. This adjustment was reported by Reuters on August 5, 2026, at 12:21 PM. The article provides this key financial action without further elaborating on the reasons behind the target price cut.
2026-08-05 06:11:59
IDEAYA Biosciences (IDYA) stock saw a modest increase after its Q2 2026 earnings report, which highlighted significant revenue growth but also widening net losses. While the company achieved substantial revenue traction and secured new funding, its increasing cash burn and lack of a clear path to profitability raise concerns for investors. The article suggests that despite positive developments in its pipeline, the high P/S ratio and deep losses could signal a value trap.
2026-08-05 03:40:53
IDEAYA Biosciences (IDYA) announced positive results from its registrational Phase 2/3 OptimUM-02 trial for darovasertib plus crizotinib in metastatic uveal melanoma, meeting its primary endpoint with a median progression-free survival (PFS) of 6.9 months compared to 3.1 months for the investigator's choice arm. The company is proceeding with an NDA filing under the FDA’s real-time oncology review program, targeting completion in the second half of 2026. IDEAYA also reported strong financial results for Q2 2026, ending the quarter with $1.24 billion in cash, cash equivalents, and marketable securities, extending its cash runway guidance into 2030.
2026-08-04 10:11:17
IDEAYA Biosciences (IDYA) reported a Q2 2026 net loss of $112.5 million ($1.22 per share) on collaboration revenue of $8.9 million, up from the prior quarter. The company announced its cash, cash equivalents, and marketable securities reached $1.24 billion, with cash runway guidance into 2030 remaining unchanged. IDEAYA also reported that its OptimUM-02 trial met its primary endpoint, leading to an NDA filing, and detailed upcoming data presentations and a new collaboration with Roche for a Phase 1 combination trial.
